A Randomized Pilot Trial Evaluating the Impact of a Yoga Intervention on Cognition in Older Adults Infected With HIV
- Conditions
- Quality of LifeMobility LimitationDepressionHIV/AIDSBalance ProblemsCognitive ImpairmentAgingMedication Adherence
- Interventions
- Other: Yoga-mindfulness
- Registration Number
- NCT03071562
- Lead Sponsor
- Adria Quigley
- Brief Summary
Approximately 50% of people living with HIV (and as many as 80% over the age of 50) have difficulties with cognitive functions such as memory and thinking that can have a profound negative impact on activities of daily living and quality of life. Problems with memory and thinking are also associated with forgetting to take anti-retroviral drugs and experiencing challenges to balance, walking and mental health (anxiety and depression). There is increasing evidence that, in the general population, exercise has positive effects on cognition, physical functioning and mental health. Despite the recognition of multiple therapeutic benefits of exercise, little attention has been paid to its possible effects on cognition in people living with HIV. The purpose of the proposed pilot study is to compare the effects of a 12-week, randomly assigned, community-based yoga-mindfulness intervention on cognition, balance, walking, mental health and quality of life in 30 people \>35 years of age living with HIV in the Halifax area. Yoga is of particular interest because it encompasses not only the physical but also spiritual, emotional, and mental dimensions of life. As such, it has tremendous potential to help stave off some of the devastating consequences of HIV infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
- Participant self-report of HIV diagnosis
- Identified cognitive concerns on the C3Q (Communicating Cognitive Challenges in HIV Questionnaire)
- Residence in the Halifax area
- Capacity to provide informed consent
- Aged 35 or older
- If participants present with contraindications to exercise, they will be excluded from the study. If participants have participated in a yoga program within the past 6 months, they will be excluded.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Yoga-mindfulness Yoga-mindfulness Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
- Primary Outcome Measures
Name Time Method B-CAM (Brief Cognitive Ability Measure) Will be assessed at baseline and 12 weeks. Cognitive function will be measured using the Brief Cognitive Ability (B-CAM), a computerized cognitive test developed using Rasch Measurement Theory and Analysis that takes 30 minutes to administer.
C3Q (Communicating Cognitive Challenges in HIV Questionnaire) Will be assessed during screening, baseline, and 12 weeks. Self-reported cognition will be assessed using the C3Q (Communicating Cognitive Challenges in HIV Questionnaire).
- Secondary Outcome Measures
Name Time Method Balance Assessed at baseline and at 12 weeks. Balance will be measured using the Community Balance and Mobility test (CB\&M).
Depression Assessed at baseline and at 12 weeks. Depression will be assessed using the Hospital Anxiety and Depression Scale, a self-report questionnaire.
Feasibility (Post-participation questionnaire) Assessed at 12 weeks. Many domains of feasibility will be assessed using a post-intervention questionnaire with questions related to participant comfort, satisfaction, safety, attendance, and time commitment.
Walking Speed Assessed at baseline and at 12 weeks. Walking peed will be measured using the 10-meter walking test because it is a simple, well-recognized global health indicator that can predict survival probability.
Medication Adherence Assessed at baseline and at 12 weeks. Participants will also be asked about Medication adherence (specifically antiretroviral) using the Simplified Medication Adherence Questionnaire (SMAQ).
Health-related Quality of Life Assessed at baseline and at 12 weeks. Quality of life will be assessed using MOS-HIV, consisting of 10 domains (health perceptions, physical/role/ social functioning, pain, mental health, vitality, health distress, cognitive function, QOL).
Trial Locations
- Locations (1)
HIV clinic
🇨🇦Halifax, Nova Scotia, Canada